Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor lonafarnib administered twice daily to pediatric patients with advanced central nervous system tumors using a modified continuous reassessment method: A pediatric brain tumor consortium study

Mark W. Kieran, Roger J. Packer, Arzu Onar, Susan M. Blaney, Peter Phillips, Ian F. Pollack, J. Russell Geyer, Sri Gururangan, Anu Banerjee, Stewart Goldman, Christopher D. Turner, Jean B. Belasco, Alberto Broniscer, Yali Zhu, Emily Frank, Paul Kirschmeier, Paul Statkevich, Antoine Yver, James M. Boyett, Larry E. Kun

Research output: Contribution to journal › Article › peer-review

59 Scopus citations

Fingerprint

Dive into the research topics of 'Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor lonafarnib administered twice daily to pediatric patients with advanced central nervous system tumors using a modified continuous reassessment method: A pediatric brain tumor consortium study'. Together they form a unique fingerprint.

Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor lonafarnib administered twice daily to pediatric patients with advanced central nervous system tumors using a modified continuous reassessment method: A pediatric brain tumor consortium study

Fingerprint

Medicine & Life Sciences